Find out more about how RYDAPT is given with your chemotherapy treatment.
For U.S. Residents Only
What is RYDAPT?
RYDAPT® (midostaurin) capsules is an oral medicine approved by the FDA to treat newly diagnosed FLT3-positive AML. RYDAPT belongs to a group of therapies called protein kinase inhibitors. Protein kinases are enzymes that send signals to help cells grow and divide. Blocking them may help prevent leukemia cells from growing. RYDAPT is thought to block the action of several kinases of leukemia cells, which may help prevent these cells from dividing and growing.
At the start of your newly diagnosed FLT3-positive AML treatment, RYDAPT is always used together with chemotherapy.
How does RYDAPT work?
RYDAPT is a type of targeted therapy that is given, along with standard chemotherapy, to treat newly diagnosed FLT3+ AML. It is not chemotherapy.
RYDAPT is thought to work by blocking the signals that help certain cells grow and divide. Blocking these signals may help kill leukemia cells in the blood and bone marrow.
How can FLT3-mutated AML be treated?
Following your initial AML diagnosis, your doctor will order a test to determine your FLT3 status. If you test positive for FLT3, you may receive at least one of the following treatments:
- RYDAPT plus chemotherapy
- Stem cell transplantation
Your treatment plan will most likely include several stages
AML is a disease that can get worse very quickly. That means your doctor will likely start your treatment right away in the hospital. Treatment usually consists of two phases. Click here to find out more on our “How to Take Treatment” page.
View the support offerings for eligible patients taking RYDAPT (PDF).